COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB EMTANSINE VERSUS PERTUZUMAB WITH TRASTUZUMAB FOR CHINESE PATIENTS WITH RESIDUAL INVASIVE HER2-POSITIVE EARLY BREAST CANCER

被引：0
|
作者：
Guan, X. [1 ]
Li, H. C. [1 ]
Xia, Y. [2 ]
Yang, Q. [2 ]
Ma, A. X. [1 ]
机构：
[1] China Pharmaceut Univ, Nanjing 32, Peoples R China
[2] Shanghai Roche Pharmaceut Ltd, Shanghai, Peoples R China
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE197
引用
下载
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [22] COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA
    Guan, X.
    Li, H.
    Chen, Q.
    Hao, C.
    Li, J.
    Wang, Y.
    Zhang, J.
    Xu, H.
    Liu, C.
    Chu, Y.
    Ma, A.
    VALUE IN HEALTH, 2019, 22 : S405 - S406
  • [23] Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis
    Khoirunnisa, Sudewi Mukaromah
    Suryanegara, Fithria Dyah Ayu
    Setiawan, Didik
    Postma, Maarten Jacobus
    de Jong, Lisa Aniek
    PLOS ONE, 2024, 19 (05):
  • [24] Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
    Luo, Yang
    Li, Wei
    Jiang, Zefei
    Zhang, Qingyuan
    Wang, Liwei
    Mao, Yixiang
    Tjan-Heijnen, Vivianne C. G.
    Im, Seock-Ah
    McConnell, Robin
    Bejarano, Sara
    Fumagalli, Debora
    Bines, Jose
    Wang, Bei
    Garg, Amit
    Kirschbrown, Whitney P.
    Xu, Binghe
    ANTI-CANCER DRUGS, 2019, 30 (08) : 866 - 872
  • [25] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [26] Correction to: Trastuzumab Emtansine: A Review of Its Adjuvant Use in Residual Invasive HER2-Positive Early Breast Cancer
    Katherine A. Lyseng-Williamson
    Drugs, 2020, 80 : 2001 - 2001
  • [27] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [28] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [29] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
  • [30] Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Garrison, Louis R., Jr.
    Lubeck, Deborah
    Lalla, Deepa
    Paton, Virginia
    Dueck, Amylou
    Perez, Edith A.
    CANCER, 2007, 110 (03) : 489 - 498
12345